Innovative nanotechnologies for enhancing nucleic acids/gene therapy: Controlling intracellular trafficking to targeted biodistribution.

[1]  Ryan L Setten,et al.  The current state and future directions of RNAi-based therapeutics , 2019, Nature Reviews Drug Discovery.

[2]  M. Tokeshi,et al.  Understanding structure‐activity relationships of pH‐sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[3]  I. Khalil,et al.  Lung‐Endothelium‐Targeted Nanoparticles Based on a pH‐Sensitive Lipid and the GALA Peptide Enable Robust Gene Silencing and the Regression of Metastatic Lung Cancer , 2019, Advanced Functional Materials.

[4]  H. Harashima,et al.  Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting , 2018, International journal of nanomedicine.

[5]  Takashi Nakamura,et al.  DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[6]  Takashi Nakamura,et al.  Application of BCG-CWS as a Systemic Adjuvant by Using Nanoparticulation Technology. , 2018, Molecular pharmaceutics.

[7]  I. Khalil,et al.  Optimization of siRNA delivery to target sites: issues and future directions , 2018, Expert opinion on drug delivery.

[8]  H. Harashima,et al.  Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Takashi Nakamura,et al.  Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core. , 2018, Molecular pharmaceutics.

[10]  I. Khalil,et al.  Synergism between a cell penetrating peptide and a pH‐sensitive cationic lipid in efficient gene delivery based on double‐coated nanoparticles , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[11]  T. Ishikawa,et al.  Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[12]  M. Tokeshi,et al.  Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems☆ , 2018, Advanced drug delivery reviews.

[13]  I. Khalil,et al.  An efficient PEGylated gene delivery system with improved targeting: Synergism between octaarginine and a fusogenic peptide. , 2018, International journal of pharmaceutics.

[14]  J. Abe,et al.  Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin‐induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[15]  H. Harashima,et al.  Optical control of mitochondrial reductive reactions in living cells using an electron donor-acceptor linked molecule. , 2017, Nanoscale.

[16]  K. Young,et al.  PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? , 2017, Front. Immunol..

[17]  M. Kohara,et al.  Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell‐mediated lipid nanoparticle‐associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Noritada Kaji,et al.  Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers , 2017, PloS one.

[19]  Takashi Nakamura,et al.  Integration of nano drug-delivery system with cancer immunotherapy. , 2017, Therapeutic delivery.

[20]  H. Harashima,et al.  pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes. , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[21]  T. Ishikawa,et al.  Validation of the use of an artificial mitochondrial reporter DNA vector containing a Cytomegalovirus promoter for mitochondrial transgene expression. , 2017, Biomaterials.

[22]  Takashi Nakamura,et al.  Modifying Cationic Liposomes with Cholesteryl-PEG Prevents Their Aggregation in Human Urine and Enhances Cellular Uptake by Bladder Cancer Cells. , 2017, Biological & pharmaceutical bulletin.

[23]  Takashi Nakamura,et al.  Development of a multifunctional envelope-type nano device and its application to nanomedicine. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Takashi Nakamura,et al.  Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines , 2016, Scientific Reports.

[25]  H. Harashima,et al.  MITO-Porter for Mitochondrial Delivery and Mitochondrial Functional Analysis. , 2016, Handbook of experimental pharmacology.

[26]  P. Cullis,et al.  Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[27]  N. Kaji,et al.  Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[28]  H. Harashima,et al.  A Dual-Ligand Liposomal System Composed of a Cell-Penetrating Peptide and a Mitochondrial RNA Aptamer Synergistically Facilitates Cellular Uptake and Mitochondrial Targeting. , 2016, Journal of pharmaceutical sciences.

[29]  H. Harashima,et al.  Relationship Between the Physicochemical Properties of Lipid Nanoparticles and the Quality of siRNA Delivery to Liver Cells. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  Hideyoshi Harashima,et al.  A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[31]  K. Chayama,et al.  Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. , 2016, Journal of hepatology.

[32]  新津 洋司郎,et al.  HSP47 siRNAを用いた線維症治療薬の開発～ビタミンA修飾リポソームによる星細胞標的化DDS～ , 2016 .

[33]  H. Ishihara,et al.  siRNA-lipid nanoparticles with long-term storage stability facilitate potent gene-silencing in vivo. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[34]  T. Ishikawa,et al.  Validation of Mitochondrial Gene Delivery in Liver and Skeletal Muscle via Hydrodynamic Injection Using an Artificial Mitochondrial Reporter DNA Vector. , 2015, Molecular pharmaceutics.

[35]  H. Harashima,et al.  Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier. , 2015, International journal of pharmaceutics.

[36]  Takashi Nakamura,et al.  Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[37]  S. Haga,et al.  Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[38]  A. Zimmer,et al.  Protamine-oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  Takashi Nakamura,et al.  Influence of Endosomal Escape and Degradation of α-Galactosylceramide Loaded Liposomes on CD1d Antigen Presentation. , 2015, Molecular pharmaceutics.

[40]  H. Harashima,et al.  Hyaluronic acid controls the uptake pathway and intracellular trafficking of an octaarginine-modified gene vector in CD44 positive- and CD44 negative-cells. , 2015, Biomaterials.

[41]  H. Nishiyama,et al.  Mechanism responsible for the antitumor effect of BCG-CWS using the LEEL method in a mouse bladder cancer model. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[42]  Takashi Nakamura,et al.  Multifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting in vivo. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[43]  H. Harashima,et al.  Instructions for use Title Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain , 2017 .

[44]  Takashi Nakamura,et al.  A new adjuvant delivery system 'cyclic di-GMP/YSK05 liposome' for cancer immunotherapy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[45]  Robert Langer,et al.  Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity , 2014, Nature Communications.

[46]  H. Harashima,et al.  An apolipoprotein E modified liposomal nanoparticle: ligand dependent efficiency as a siRNA delivery carrier for mouse-derived brain endothelial cells. , 2014, International journal of pharmaceutics.

[47]  Y. Hirata,et al.  In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus. , 2014, Scientific Reports.

[48]  N. Kaji,et al.  Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes , 2014, Molecular therapy. Nucleic acids.

[49]  M. Glickman,et al.  The mechanism of action of BCG therapy for bladder cancer—a current perspective , 2014, Nature Reviews Urology.

[50]  H. Nishiyama,et al.  Nanoparticulation of BCG-CWS for application to bladder cancer therapy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[51]  Robert Langer,et al.  Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates , 2014, Proceedings of the National Academy of Sciences.

[52]  H. Harashima,et al.  RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[53]  N. Minakawa,et al.  The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[54]  Hideyoshi Harashima,et al.  The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[55]  N. Minakawa,et al.  In vitro optimization of 2′-OMe-4′-thioribonucleoside–modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle , 2013, Nucleic acids research.

[56]  Takahiro Nomoto,et al.  Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium. , 2013, ACS nano.

[57]  K. G. Rajeev,et al.  Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[59]  H. Harashima,et al.  Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[60]  Hideyoshi Harashima,et al.  Incorporation of polyinosine-polycytidylic acid enhances cytotoxic T cell activity and antitumor effects by octaarginine-modified liposomes encapsulating antigen, but not by octaarginine-modified antigen complex. , 2013, International journal of pharmaceutics.

[61]  Scott A Barros,et al.  Safety profile of RNAi nanomedicines. , 2012, Advanced drug delivery reviews.

[62]  H. Harashima,et al.  A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[63]  H. Harashima,et al.  Pretreatment of hepatocyte growth factor gene transfer mediated by octaarginine peptide-modified nanoparticles ameliorates LPS/D-galactosamine-induced hepatitis. , 2012, Nucleic acid therapeutics.

[64]  G. Kibria,et al.  Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[65]  Nathan M Belliveau,et al.  Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA , 2012, Molecular therapy. Nucleic acids.

[66]  D. Peter Tieleman,et al.  Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core , 2012, The journal of physical chemistry. C, Nanomaterials and interfaces.

[67]  Shigeo Matsuda,et al.  Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** , 2012, Angewandte Chemie.

[68]  W. Hauswirth,et al.  Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber’s hereditary optic neuropathy in a mouse model , 2012, Proceedings of the National Academy of Sciences.

[69]  S. Adhya,et al.  Modulation of mitochondrial respiratory capacity by carrier-mediated transfer of RNA in vivo. , 2012, Mitochondrion.

[70]  T Nakamura,et al.  A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications. , 2012, Accounts of chemical research.

[71]  Ismail Hafez,et al.  Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[72]  H. Harashima,et al.  Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter. , 2012, Biomaterials.

[73]  D. Maysinger,et al.  Design and evaluation of multifunctional nanocarriers for selective delivery of coenzyme Q10 to mitochondria. , 2012, Biomacromolecules.

[74]  I. Khalil,et al.  Octaarginine- and pH sensitive fusogenic peptide-modified nanoparticles for liver gene delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[75]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[76]  J. Yamauchi,et al.  Cell penetrating peptide-mediated systemic siRNA delivery to the liver. , 2011, International journal of pharmaceutics.

[77]  V. Weissig.  From Serendipity to Mitochondria-Targeted Nanocarriers , 2011, Pharmaceutical Research.

[78]  H. Harashima,et al.  Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[79]  Takashi Nakamura,et al.  A20 silencing by lipid envelope-type nanoparticles enhances the efficiency of lipopolysaccharide-activated dendritic cells. , 2011, Biological & pharmaceutical bulletin.

[80]  G. Kibria,et al.  Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[81]  Daisuke Morita,et al.  A Microbial Glycolipid Functions as a New Class of Target Antigen for Delayed-type Hypersensitivity* , 2011, The Journal of Biological Chemistry.

[82]  A. Sachs,et al.  Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[83]  D. Levorse,et al.  Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions. , 2011, Langmuir : the ACS journal of surfaces and colloids.

[84]  M. Teitell,et al.  PNPASE Regulates RNA Import into Mitochondria , 2010, Cell.

[85]  S. Futaki,et al.  Reprint of: Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[86]  M. King,et al.  Genetic Heterogeneity in Human Disease , 2010, Cell.

[87]  Robert W. Taylor,et al.  Mitochondrial DNA mutations and human disease. , 2010, Biochimica et biophysica acta.

[88]  Kathryn A. Whitehead,et al.  Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.

[89]  K. Takami,et al.  Innate immune therapy with a Bacillus Calmette-Guérin cell wall skeleton after radical surgery for non-small cell lung cancer: A case-control study , 2009, Surgery Today.

[90]  H. Harashima,et al.  Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. , 2008, Advanced drug delivery reviews.

[91]  S. Futaki,et al.  Octaarginine- and Octalysine-modified Nanoparticles Have Different Modes of Endosomal Escape* , 2008, Journal of Biological Chemistry.

[92]  Robert Langer,et al.  Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.

[93]  Hideyoshi Harashima,et al.  Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[94]  S. Duvezin-Caubet,et al.  Mammalian mitochondria have the innate ability to import tRNAs by a mechanism distinct from protein import , 2008, Proceedings of the National Academy of Sciences.

[95]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[96]  S. Futaki,et al.  Octaarginine-modified liposomes: enhanced cellular uptake and controlled intracellular trafficking. , 2008, International journal of pharmaceutics.

[97]  Yuma Yamada,et al.  Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system. , 2008, Advanced drug delivery reviews.

[98]  Takenori Yamamoto,et al.  MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. , 2008, Biochimica et biophysica acta.

[99]  Leaf Huang,et al.  Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. , 2007, Molecular immunology.

[100]  Shiroh Futaki,et al.  Octaarginine-modified multifunctional envelope-type nano device for siRNA. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[101]  H Akita,et al.  Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery , 2007, Gene Therapy.

[102]  Y. Pak,et al.  DNA delivery to the mitochondria sites using mitochondrial leader peptide conjugated polyethylenimine , 2007, Journal of drug targeting.

[103]  S. Adhya,et al.  Functional Delivery of a Cytosolic tRNA into Mutant Mitochondria of Human Cells , 2006, Science.

[104]  Shubiao Zhang,et al.  Toxicity of cationic lipids and cationic polymers in gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[105]  A. Schapira,et al.  Mitochondrial disease , 2006, The Lancet.

[106]  S. Adhya,et al.  A bifunctional tRNA import receptor from Leishmania mitochondria. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[107]  Shiroh Futaki,et al.  High Density of Octaarginine Stimulates Macropinocytosis Leading to Efficient Intracellular Trafficking for Gene Expression* , 2006, Journal of Biological Chemistry.

[108]  J. Kamps,et al.  The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. , 2005, Biochemical and biophysical research communications.

[109]  Shiroh Futaki,et al.  Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[110]  F. Szoka,et al.  GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. , 2004, Advanced drug delivery reviews.

[111]  H Harashima,et al.  Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation , 2004, Gene Therapy.

[112]  Vladimir P Torchilin,et al.  DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[113]  D. Murdock,et al.  Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[114]  H Harashima,et al.  Stearylated arginine-rich peptides: a new class of transfection systems. , 2001, Bioconjugate chemistry.

[115]  V. Torchilin,et al.  DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[116]  H. Maeda,et al.  Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[117]  I. Azuma,et al.  Development of immunoadjuvants for immunotherapy of cancer. , 2001, International immunopharmacology.

[118]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[119]  D. Wallace.  Mitochondrial diseases in man and mouse. , 1999, Science.

[120]  G. Schatz.  The Protein Import System of Mitochondria* , 1996, The Journal of Biological Chemistry.

[121]  H. Akaza,et al.  [Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Bladder cancer BCG Study Group]. , 1992, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[122]  I. Nonaka,et al.  A mutation in the tRNALeu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies , 1990, Nature.

[123]  N. A. Duffie,et al.  Synthesis of heterarchical manufacturing systems , 1990 .

[124]  隆司 梅田,et al.  膀胱移行上皮内癌および表在性膀胱癌に対するBCG (Tokyo 172株) 膀胱内注入療法効果の解析 , 1989 .

[125]  T. Ochiai,et al.  Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton , 1983, Cancer Immunology, Immunotherapy.

[126]  K. Yasumoto,et al.  Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin. , 1979, Cancer research.

[127]  Takashi Nakamura,et al.  Innovative Technologies in Nanomedicines: From Passive Targeting to Active Targeting/From Controlled Pharmacokinetics to Controlled Intracellular Pharmacokinetics. , 2017, Macromolecular bioscience.

[128]  Takashi Nakamura,et al.  Multifunctional enveloped nanodevices (MENDs). , 2014, Advances in genetics.

[129]  H. Harashima,et al.  Multifunctional envelope-type nano device (MEND) for organelle targeting via a stepwise membrane fusion process. , 2012, Methods in enzymology.

[130]  S. Futaki,et al.  Application of a fusiogenic peptide GALA for intracellular delivery. , 2011, Methods in molecular biology.

[131]  S. Stirdivant,et al.  Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[132]  S. Futaki,et al.  Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[133]  K. G. Rajeev,et al.  Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[134]  E. Wisse,et al.  The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer , 2008, Gene Therapy.

[135]  S. Futaki.  Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. , 2006, Biopolymers.

[136]  B. Zbar,et al.  Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. , 1974, Journal of the National Cancer Institute.